3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
4
Phase 2
3
Phase 1/2
2
Phase NA
1
Phase 1
1
Status
Active not recruiting
2
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Gynecologic
2
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
298
Carcinoma, Non-Small-Cell Lung
224
Prostatic Neoplasms
154
Neoplasms
154
Multiple Myeloma
116
Neoplasm Metastasis
83
Colorectal Neoplasms
80
Leukemia, Myeloid, Acute
73
Lung Neoplasms
71
Parkinson Disease 4, Autosomal Dominant Lewy Body
68
Melanoma
67
Leukemia, Lymphocytic, Chronic, B-Cell
63
Lymphoma, Follicular
62
Lymphoma, Non-Hodgkin
61
Papillomavirus Infections
59
Leukemia
59
Pain
52
Lymphoma
52
Uterine Cervical Neoplasms
50
Precursor Cell Lymphoblastic Leukemia-Lymphoma
49
Ovarian Neoplasms
46
Carcinoma, Hepatocellular
46
Keratosis, Actinic
44
Carcinoma, Renal Cell
44
Recurrence
43
Head and Neck Neoplasms
43
Stomach Neoplasms
38
Lymphoma, Large B-Cell, Diffuse
34
Urinary Bladder Neoplasms
33
Squamous Cell Carcinoma of Head and Neck
32
Interventions
ruxolitinib
1
rucaparib
1
olaparib
1
cc-486
1
Nivolumab
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Phase 3
×
Has results
×
Pathologic Complete Response
×
Clear all
NCT01844986
2025-12-10
SOLO-1
AstraZeneca
Phase 3
Active not recruiting
450 enrolled
18 charts
1 FDA
NCT01757535
2025-07-08
QUAZAR AML-001
Celgene
Phase 3
Completed
472 enrolled
24 charts
1 FDA
NCT03522246
2025-06-24
ATHENA
pharmaand GmbH
Phase 3
Active not recruiting
1,097 enrolled
26 charts
NCT04934670
2024-08-27
2002
Xenikos
Phase 3
Terminated
12 enrolled
12 charts